Home » Drug Information
Recently Approved Drugs
The following database contains a listing of drugs approved by the Food and Drug Administration (FDA) for sale in the United States. The database is searchable by year or by medical area. Drug information typically includes the drug name, approval status, indication of use, and clinical trial results.
Find out more about the types of drugs included in this listing.
Year: 2009 | 2008 | [2007] | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | View By Medical Area
Azor (amlodipine besylate; olmesartan medoxomil); Daiichi Sankyo;
For the treatment of hypertension, Approved September 2007
Fenofibrate; LifeCycle Pharma;
For the treatment of hyperlipidemia, dyslipidemia and hypertriglyceridemia, Approved August 2007
Letairis (ambrisentan); Gilead;
For the treatment of pulmonary arterial hypertension, Approved June 2007
Soliris (eculizumab); Alexion Pharm;
For the treatment of paroxysmal nocturnal hemoglobinuria, Approved March 2007
Tekturna (aliskiren); Novartis Pharms;
For the treatment of hypertension, Approved March 2007
Altabax (retapamulin); Glaxo;
For the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes, Approved April 2007
Extina (ketoconazole); Stiefel;
For the treatment of seborrheic dermatitis, Approved June 2007
Xyzal (levocetirizine dihydrochloride); UCB Inc.;
For the treatment of seasonal and perennial allergic rhinitis and urticaria, Approved May 2007
Evamist (estradiol); Vivus;
For the treatment of moderate to severe vasomotor symptoms due to menopause, Approved July 2007
Fenofibrate; LifeCycle Pharma;
For the treatment of hyperlipidemia, dyslipidemia and hypertriglyceridemia, Approved August 2007
Somatuline Depot (lanreotide acetate); Beaufour Ipsen;
For the treatment of acromegaly, Approved August 2007
Supprelin LA (histrelin acetate); Indevis Pharms;
For the treatment of central precocious puberty, Approved May 2007
Kuvan (sapropterin dihydrochloride); Biomarin;
For the treatment of hyperphenylalaninemia due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria, Approved December 2007
Mircera (methoxy polyethylene glycol-epoetin beta); Hoffman La-Roche;
For the treatment of anemia associated with chronic renal failure, Approved November 2007
Soliris (eculizumab); Alexion Pharm;
For the treatment of paroxysmal nocturnal hemoglobinuria, Approved March 2007
Altabax (retapamulin); Glaxo;
For the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes, Approved April 2007
AzaSite (azithromycin); InSite Vision;
For the treatment of bacterial conjunctivitis, Approved April 2007
Doribax (doripenem); Johnson & Johnson;
For the treatment of intra-abdominal infections and urinary tract infections, Approved October 2007
Extina (ketoconazole); Stiefel;
For the treatment of seborrheic dermatitis, Approved June 2007
Isentress (raltegravir); Merck;
For the treatment of HIV-1, Approved October 2007
Selzentry (maraviroc); Pfizer;
For the treatment of CCR5-tropic HIV-1, Approved August 2007
Veramyst (fluticasone furoate); GlaxoSmithKline;
For the treatment of seasonal and perennial allergic rhinitis, Approved April 2007
Xyzal (levocetirizine dihydrochloride); UCB Inc.;
For the treatment of seasonal and perennial allergic rhinitis and urticaria, Approved May 2007
Evista (raloxifene hydrochloride); Eli Lilly;
For the treatment/prevention of osteoporosis and reduction of breast cancer risk in postmenopausal women, Approved September 2007
Reclast (zoledronic acid); Novartis;
For the treatment of postmenopausal osteoporosis, Approved August 2007
Reclast (zoledronic acid); Novartis Pharms;
For the treatment of Paget's disease, Approved April 2007
Somatuline Depot (lanreotide acetate); Beaufour Ipsen;
For the treatment of acromegaly, Approved August 2007
Doribax (doripenem); Johnson & Johnson;
For the treatment of intra-abdominal infections and urinary tract infections, Approved October 2007
Mircera (methoxy polyethylene glycol-epoetin beta); Hoffman La-Roche;
For the treatment of anemia associated with chronic renal failure, Approved November 2007
Torisel (temsirolimus); Wyeth Pharms;
For the treatment of renal cell carcinoma, Approved May 2007
Exelon (rivastigmine tartrate); Novartis Pharms;
For the treatment of Alzheimer's and Parkinson's disease-related dementia, Approved July 2007
Neupro (rotigotine); Schwarz;
For the treatment of Parkinson's disease, Approved May 2007
Nuvigil (armodafinil); Cephalon;
For the treatment of excessive sleepiness, Approved June 2007
Vyvanse (Lisdexamfetamine Dimesylate); New River;
For the treatment of Attention-Deficit/Hyperactivity Disorder, Approved February 2007
Evamist (estradiol); Vivus;
For the treatment of moderate to severe vasomotor symptoms due to menopause, Approved July 2007
Evista (raloxifene hydrochloride); Eli Lilly;
For the treatment/prevention of osteoporosis and reduction of breast cancer risk in postmenopausal women, Approved September 2007
Reclast (zoledronic acid); Novartis;
For the treatment of postmenopausal osteoporosis, Approved August 2007
Evista (raloxifene hydrochloride); Eli Lilly;
For the treatment/prevention of osteoporosis and reduction of breast cancer risk in postmenopausal women, Approved September 2007
Hycamtin (topotecan); GlaxoSmithKline;
For the treatment of small cell lung cancer, Approved October 2007
Ixempra (ixabepilone); Bristol Myers Squibb;
For the treatment of breast cancer, Approved October 2007
Tasigna (nilotinib hydrochloride monohydrate); Novartis;
For the treatment of chronic myelogenous leukemia, Approved October 2007
Torisel (temsirolimus); Wyeth Pharms;
For the treatment of renal cell carcinoma, Approved May 2007
Tykerb (lapatinib); GlaxoSmithKline;
For the treatment of breast cancer, Approved March 2007
AzaSite (azithromycin); InSite Vision;
For the treatment of bacterial conjunctivitis, Approved April 2007
Veramyst (fluticasone furoate); GlaxoSmithKline;
For the treatment of seasonal and perennial allergic rhinitis, Approved April 2007
Xyzal (levocetirizine dihydrochloride); UCB Inc.;
For the treatment of seasonal and perennial allergic rhinitis and urticaria, Approved May 2007
Altabax (retapamulin); Glaxo;
For the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes, Approved April 2007
Supprelin LA (histrelin acetate); Indevis Pharms;
For the treatment of central precocious puberty, Approved May 2007
Veramyst (fluticasone furoate); GlaxoSmithKline;
For the treatment of seasonal and perennial allergic rhinitis, Approved April 2007
Vyvanse (Lisdexamfetamine Dimesylate); New River;
For the treatment of Attention-Deficit/Hyperactivity Disorder, Approved February 2007
Xyzal (levocetirizine dihydrochloride); UCB Inc.;
For the treatment of seasonal and perennial allergic rhinitis and urticaria, Approved May 2007
Zingo (lidocaine hydrochloride monohydrate); Anesiva;
For local analgesia prior to venipuncture or peripheral intravenous cannulation,
in children 3 to 18 years of age, Approved August 2007
Vyvanse (Lisdexamfetamine Dimesylate); New River;
For the treatment of Attention-Deficit/Hyperactivity Disorder, Approved February 2007
Letairis (ambrisentan); Gilead;
For the treatment of pulmonary arterial hypertension, Approved June 2007
Xyzal (levocetirizine dihydrochloride); UCB Inc.;
For the treatment of seasonal and perennial allergic rhinitis and urticaria, Approved May 2007
